StreetInsider.com News Articles

IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses

Thu, 23 Jul 2026 08:15:00 -0400

Boston, Massachusetts--(Newsfile Corp. - July 23, 2026) - Block & Leviton is investigating Immix Biopharma (NASDAQ: IMMX) for potential securities law violations. Investors who have lost money in their Immix Biopharma investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/immx.

What is this all about?

Block & Leviton is investigating whether Immix Biopharma or certain of its executives violated federal securities laws. According to news reports, a person who had been serving as an Immix executive under the name "Richard Graydon" was in fact allegedly a Rhode Island most-wanted fugitive

IMMX INVESTIGATION: Securities Fraud Investigation by Block & Leviton Could Allow Immix Biopharma Investors to Recover Losses

Thu, 23 Jul 2026 08:15:00 -0400

What is this all about?

Needham Starts Immix Biopharma, Inc. (IMMX) at Buy

Wed, 22 Jul 2026 06:55:22 -0400

Needham analyst Gil Blum initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $21.00.

For an analyst ratings summary and ratings history on Immix Biopharma, Inc. click here. For more ratings news on Immix Biopharma, Inc. click here.

Shares of Immix Biopharma, Inc. closed at $9.57 yesterday.

Immix Biopharma shares fall 13% after executive arrested as fugitive

Mon, 20 Jul 2026 12:15:07 -0400

Shares of Immix Biopharma, Inc. (NASDAQ: IMMX) fell more than 13% during intraday trading on July 20, 2026, after a report revealed that a company executive had been arrested as a long-sought fugitive.

According to a report by STAT News, Ronald Fischer, 70, a former anesthesiologist who disappeared in 2005 while on trial for first-degree sexual assault, had been working as an executive at Immix Biopharma. Federal and Rhode Island authorities arrested Fischer after tracking and boarding a 56-foot sailboat off the coast of New Jersey.

Kehoe Law Firm, P.C., a Philadelphia-based plaintiff-side law firm, stated it is investigating potential securities fraud

Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims

Mon, 20 Jul 2026 12:13:00 -0400

Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma") (NASDAQ: IMMX).

On July 20, 2026, Investing.com reported that "Immix Biopharma Inc . . . shares fell 13% . . . after STAT News reported that one of Rhode Island's most-wanted fugitives appears to have been working as an executive at the company."

Additionally, "[a]ccording to the report, Ronald Fischer, 70, was arrested last week by federal and Rhode Island authorities after they tracked and boarded a 56-foot sailboat off

Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims

Mon, 20 Jul 2026 12:13:00 -0400

Additionally, "[a]ccording to the report, Ronald Fischer, 70, was arrested last week by federal and Rhode Island authorities after they tracked and boarded a 56-foot sailboat off

Form 8-K Immix Biopharma, Inc. For: Jul 20

Mon, 20 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26786553.html

Form 8-K Immix Biopharma, Inc. For: Jul 20

Mon, 20 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260720/26786553.html

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

The analyst comments "We initiate coverage of IMMX with a Buy rating and $27 PO. IMMX is developing NXC201 for AL amyloidosis, a rare disease with damaged vital organs and no approved treatments. Early data of NXC-201 shows ~95% complete response and rapid minimal residual disease in relapsed/refractory (r/r) AL amyloidosis. The safety profile was favorable for patients facing potential organ failure with no observed neurotoxicity. Updated phase 2 data is

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

BofA Securities Starts Immix Biopharma, Inc. (IMMX) at Buy

Thu, 18 Jun 2026 06:11:26 -0400

(Updated - June 18, 2026 6:11 AM EDT)

BofA Securities analyst Tazeen Ahmad initiates coverage on Immix Biopharma, Inc. (NASDAQ: IMMX) with a Buy rating and a price target of $27.00.

Form SCHEDULE 13G/A Immix Biopharma, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 05 Jun 2026 12:57:00 -0400

si-local-file:///var/storage/secattach/20260605/26610062.html

Form SCHEDULE 13G/A Immix Biopharma, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 05 Jun 2026 12:57:00 -0400

si-local-file:///var/storage/secattach/20260605/26610062.html

Form 8-K Immix Biopharma, Inc. For: May 22

Fri, 29 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260529/26576467.html

Form 8-K Immix Biopharma, Inc. For: May 22

Fri, 29 May 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260529/26576467.html

Form 4 Immix Biopharma, Inc. For: May 22 Filed by: Hsu Jason